Chemokines mutants having improved oral bioavailability
US7335350B2 · kind B2 · utility
0Cited by
5References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 31, 2003 |
| Grant date | Feb 26, 2008 |
| Priority date | — |
| Expiry date | Mar 31, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1β, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.